Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ORM-12741 Modified Release Formulations
NCT02303860Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Oct 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ORM-12741 in Alzheimer's disease (AD) (2 arms), sponsored by Orion Corporation. Primary endpoints: Maximum Plasma Concentration at Day 11, Time to Maximum Plasma Concentration at Day 11 and 2 more. Started Oct 2014; status: completed.
02
Drugs
ORM-12741
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02303860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303860.